Telo Genomics Corp. (TELO.V)
CAD 0.12
(0.0%)
CAD 0.12
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 375.58 Thousand CAD | 20.05% |
| 2022 | 312.86 Thousand CAD | 35.99% |
| 2021 | 230.07 Thousand CAD | 49.73% |
| 2020 | 153.65 Thousand CAD | -60.94% |
| 2019 | 393.41 Thousand CAD | -69.91% |
| 2018 | 1.3 Million CAD | 75.85% |
| 2017 | 743.53 Thousand CAD | -16.1% |
| 2016 | 886.25 Thousand CAD | 2441.66% |
| 2015 | 34.86 Thousand CAD | 113.93% |
| 2014 | 16.29 Thousand CAD | -2.16% |
| 2013 | 16.65 Thousand CAD | 22.43% |
| 2012 | 13.6 Thousand CAD | -20.76% |
| 2011 | 17.17 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 221.14 Thousand CAD | -29.32% |
| 2023 Q4 | 375.58 Thousand CAD | 46.12% |
| 2023 Q3 | 257.04 Thousand CAD | -20.01% |
| 2023 Q2 | 321.35 Thousand CAD | 45.32% |
| 2022 Q3 | 163.76 Thousand CAD | 16.04% |
| 2022 FY | 312.86 Thousand CAD | 35.99% |
| 2022 Q4 | 312.86 Thousand CAD | 91.04% |
| 2022 Q2 | 141.13 Thousand CAD | -31.87% |
| 2022 Q1 | 207.14 Thousand CAD | -9.97% |
| 2021 FY | 230.07 Thousand CAD | 49.73% |
| 2021 Q4 | 230.07 Thousand CAD | 162.75% |
| 2021 Q3 | 87.56 Thousand CAD | 11.94% |
| 2021 Q2 | 78.22 Thousand CAD | -62.01% |
| 2021 Q1 | 205.88 Thousand CAD | 33.99% |
| 2020 Q1 | 282.23 Thousand CAD | -28.26% |
| 2020 Q4 | 153.65 Thousand CAD | -23.45% |
| 2020 Q3 | 200.72 Thousand CAD | -12.14% |
| 2020 Q2 | 228.46 Thousand CAD | -19.05% |
| 2020 FY | 153.65 Thousand CAD | -60.94% |
| 2019 Q2 | 496 Thousand CAD | -69.44% |
| 2019 FY | 393.41 Thousand CAD | -69.91% |
| 2019 Q1 | 1.62 Million CAD | 24.13% |
| 2019 Q3 | 260.44 Thousand CAD | -47.49% |
| 2019 Q4 | 393.41 Thousand CAD | 51.06% |
| 2018 Q3 | 1.16 Million CAD | 10.94% |
| 2018 Q2 | 1.05 Million CAD | 5.16% |
| 2018 Q1 | 998.56 Thousand CAD | 34.3% |
| 2018 FY | 1.3 Million CAD | 75.85% |
| 2018 Q4 | 1.3 Million CAD | 12.23% |
| 2017 Q1 | 869.4 Thousand CAD | -1.9% |
| 2017 Q3 | 821.71 Thousand CAD | -30.54% |
| 2017 FY | 743.53 Thousand CAD | -16.1% |
| 2017 Q2 | 1.18 Million CAD | 36.06% |
| 2017 Q4 | 743.53 Thousand CAD | -9.51% |
| 2016 Q1 | 669.11 Thousand CAD | 8447.69% |
| 2016 FY | 886.25 Thousand CAD | 2441.66% |
| 2016 Q4 | 886.25 Thousand CAD | 38.83% |
| 2016 Q3 | 638.35 Thousand CAD | 100.27% |
| 2016 Q2 | 318.74 Thousand CAD | -52.36% |
| 2015 FY | 34.86 Thousand CAD | 113.93% |
| 2015 Q1 | 3871.00 CAD | -32.77% |
| 2015 Q2 | 34.86 Thousand CAD | 800.77% |
| 2015 Q3 | 35.96 Thousand CAD | 3.15% |
| 2015 Q4 | 7828.00 CAD | -78.23% |
| 2014 FY | 16.29 Thousand CAD | -2.16% |
| 2014 Q2 | 16.29 Thousand CAD | 427.31% |
| 2014 Q4 | 5758.00 CAD | -66.71% |
| 2014 Q3 | 17.29 Thousand CAD | 6.14% |
| 2014 Q1 | 3091.00 CAD | -46.39% |
| 2013 Q1 | 1780.00 CAD | -60.04% |
| 2013 Q2 | 16.65 Thousand CAD | 835.84% |
| 2013 Q3 | 26.37 Thousand CAD | 58.36% |
| 2013 FY | 16.65 Thousand CAD | 22.43% |
| 2013 Q4 | 5766.00 CAD | -78.14% |
| 2012 Q3 | 17.92 Thousand CAD | 31.76% |
| 2012 Q1 | 1797.00 CAD | -88.2% |
| 2012 Q2 | 13.6 Thousand CAD | 657.15% |
| 2012 Q4 | 4455.00 CAD | -75.15% |
| 2012 FY | 13.6 Thousand CAD | -20.76% |
| 2011 Q4 | 15.22 Thousand CAD | 98.33% |
| 2011 Q3 | 7676.00 CAD | 0.0% |
| 2011 FY | 17.17 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Avricore Health Inc. | 529.21 Thousand CAD | 29.03% |